Cosmo Bio Company,Limited (TYO:3386)
Japan · Delayed Price · Currency is JPY 1,225.00
+6.00 (0.49%)
Jun 4, 2026, 3:30 PM JST
Cosmo Bio Company,Limited Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 11,004 | 10,766 | 10,037 | 9,340 | 9,553 | 9,231 | |
Revenue Growth (YoY) | 8.02% | 7.26% | 7.46% | -2.23% | 3.49% | 14.08% |
Cost of Revenue | 7,225 | 7,064 | 6,708 | 6,090 | 6,112 | 5,572 |
Gross Profit | 3,779 | 3,702 | 3,329 | 3,250 | 3,441 | 3,659 |
Selling, General & Admin | 3,438 | 3,359 | 3,010 | 2,729 | 2,624 | 2,609 |
Operating Expenses | 3,438 | 3,359 | 3,010 | 2,729 | 2,624 | 2,609 |
Operating Income | 341 | 343 | 319 | 521 | 817 | 1,050 |
Interest & Investment Income | 101 | 101 | 75 | 71 | 44 | 40 |
Currency Exchange Gain (Loss) | -5 | 13 | -33 | - | -49 | -15 |
Other Non Operating Income (Expenses) | 26 | 31 | 5 | 33 | 7 | 23 |
EBT Excluding Unusual Items | 463 | 488 | 366 | 625 | 819 | 1,098 |
Gain (Loss) on Sale of Investments | 111 | 69 | 5 | - | - | - |
Gain (Loss) on Sale of Assets | -11 | -7 | - | - | - | - |
Asset Writedown | -45 | -46 | -3 | 27 | -29 | - |
Pretax Income | 518 | 504 | 368 | 652 | 790 | 1,098 |
Income Tax Expense | 171 | 170 | 99 | 191 | 238 | 330 |
Earnings From Continuing Operations | 347 | 334 | 269 | 461 | 552 | 768 |
Minority Interest in Earnings | - | 3 | -7 | -19 | -35 | -31 |
Net Income | 347 | 337 | 262 | 442 | 517 | 737 |
Net Income to Common | 347 | 337 | 262 | 442 | 517 | 737 |
Net Income Growth | 42.21% | 28.63% | -40.72% | -14.51% | -29.85% | 9.35% |
Shares Outstanding (Basic) | 6 | 6 | 6 | 6 | 6 | 6 |
Shares Outstanding (Diluted) | 6 | 6 | 6 | 6 | 6 | 6 |
Shares Change (YoY) | -1.85% | -2.21% | -0.22% | 0.40% | -0.06% | -2.01% |
EPS (Basic) | 61.11 | 59.26 | 45.05 | 75.83 | 89.06 | 126.88 |
EPS (Diluted) | 61.11 | 59.26 | 45.05 | 75.83 | 89.06 | 126.88 |
EPS Growth | 44.89% | 31.54% | -40.59% | -14.85% | -29.81% | 11.59% |
Free Cash Flow | - | 366 | 25 | 669 | 229 | 617 |
Free Cash Flow Per Share | - | 64.36 | 4.30 | 114.78 | 39.45 | 106.22 |
Dividend Per Share | 50.000 | 50.000 | 50.000 | 30.000 | 36.000 | 36.000 |
Dividend Growth | - | - | 66.67% | -16.67% | - | 5.88% |
Gross Margin | 34.34% | 34.39% | 33.17% | 34.80% | 36.02% | 39.64% |
Operating Margin | 3.10% | 3.19% | 3.18% | 5.58% | 8.55% | 11.38% |
Profit Margin | 3.15% | 3.13% | 2.61% | 4.73% | 5.41% | 7.98% |
Free Cash Flow Margin | - | 3.40% | 0.25% | 7.16% | 2.40% | 6.68% |
EBITDA | 515.75 | 510 | 455 | 669 | 958 | 1,216 |
EBITDA Margin | 4.69% | 4.74% | 4.53% | 7.16% | 10.03% | 13.17% |
D&A For EBITDA | 174.75 | 167 | 136 | 148 | 141 | 166 |
EBIT | 341 | 343 | 319 | 521 | 817 | 1,050 |
EBIT Margin | 3.10% | 3.19% | 3.18% | 5.58% | 8.55% | 11.38% |
Effective Tax Rate | 33.01% | 33.73% | 26.90% | 29.29% | 30.13% | 30.05% |